News
Optogenetics: A cool tool may have found medical use
Optogenetics is a biological technique that uses light to control neurons that have been genetically modified to express light-sensitive ion channels. As such, it is a neuromodulation method that controls the activities of individual neurons in living tissue — even...
A New Type of Antibody –
For a long time 5 antibody types have been known in mammals, IgG, IgM, IgA, IgE, and IgD, with IgG being the work horse in biotechnology. So it drew our attention that a group at Duke University has described a new type of anti-glycan antibody that binds to a patch of...
Monoclonal for Alzheimer’s
On Monday FDA approved Biogen’s aducanumab, brand name Aduhelm, through a program called accelerated approval. Aduhelm is the first new medication for Alzheimer’s disease in nearly two decades. FDA’s decision was welcomed by patients and their families as a...
San Diego #5 US Biopharma Cluster in 2020
A list of the ten top ranking biopharmaceutical clusters in the US was recently compiled by Genetic Engineering News. The list is based on available 2020 data for NIH funding, venture capital funding, patents, lab space and jobs. San Diego made #5 of the list. Yay!...
Honoring our friend and mentor, Ralph Reisfeld
Our dear friend and mentor, Ralph, passed in December after a long and fruitful life in science. Ralph leaves an important legacy as a pioneer in cancer immunotherapy and as a valued mentor, colleague and friend to many. We will miss him very much and want to share an...
Cold chain is a hot topic among investors
The Pfizer and BioNTech vaccine against COVID-19 received an emergency use authorization from the FDA last Friday, and thousands of doses are being rolled out across the country this week. But the vaccine, which must be stored at between -80 and -60 degrees Celsius, necessitates the utilization of a “cold chain” to keep it within this temperature range from the moment it leaves the manufacturing site to just before it is administered to a patient.
Positive but perplexing results from Oxford/AstraZeneca COVID vaccine trial
The University of Oxford’s COVID-19 vaccine candidate, developed in partnership with the biotech AstraZeneca, is the third vaccine this week to publicize promising data from its clinical trials. And, in a surprising twist, it appears that a lower dose of the vaccine does a better job at protecting participants from COVID than a higher dose.
Pfizer reports coronavirus vaccine with more than 90% efficacy
In what could prove to be a turning point in the fight against COVID-19, U.S. pharmaceutical giant Pfizer and German biotech company BioNTech announced yesterday that one of their coronavirus vaccines is more than 90% effective at preventing the viral disease, according to new data from its Phase III trial. They are predicting that they will have the requisite safety data for an Emergency Use Authorization from the FDA before the end of the month.
Chronic jet lag deregulates cancer cell microenvironment
Mounting evidence suggests that good sleep is critical to many aspects of our health. Circadian rhythms regulate the sleep-wake cycle in everything from mammals to fruit flies to plants, and keeps them synced up to the 24-hour cycle of the Earth’s rotation. In humans, circadian rhythms can be disrupted by chronic jet lag and shift work. New research indicates that disrupting these rhythms has negative consequences for both tumor size and microenvironment in mice.
Tiny bovine antibody fragments show big potential
In the world of monoclonal antibodies, being small is a big deal. Smaller antibodies and antibody fragments can penetrate solid tumors that would be inaccessible to larger antibodies, and some can even make it across the blood-brain barrier. That’s why it’s exciting that researchers at the University of Bath and UCB (a Belgian biotech company) have designed extra-small antibody fragments from cows.